Intellia Therapeutics Inc (NTLA) Up 4.05% in Premarket Trading

Intellia Therapeutics Inc (NTLA) is higher by Monday morning, with the stock gaining 4.05% in pre-market trading to 29.26. NTLA's short-term technical score of 7 indicates that the stock has traded less bullishly over the last month than 93% of stocks on the market. In the Biotechnology industry, which ranks 120 out of 146 industries, the stock ranks higher than 15% of stocks. Intellia Therapeutics Inc has risen 5.56% over the past month, closing at $26.32 on October 23. During this period of time, the stock fell as low as $23.16 and as high as $29.75. NTLA has an average analyst recommendation of Strong Buy. The company has an average price target of $78.45.

NTLA has an Overall Score of 36. Find out what this means to you and get the rest of the rankings on NTLA!

See Full NTLA Report

Intellia Therapeutics Inc has a Long-Term Technical rank of 10. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 90% of the market scoring higher. In the Biotechnology industry which is number 130 by this metric, NTLA ranks better than 130% of stocks.

Important Dates for Investors in NTLA:

-Intellia Therapeutics Inc is set to release earnings on 2024-02-07. Over the last 12 months, the company has reported EPS of $-5.44. -We do not have a set dividend date for Intellia Therapeutics Inc at this time. Click Here To Get The Full Report on Intellia Therapeutics Inc (NTLA)